Stock Track | Replimune Group Plummets 5% as Leerink Partners Slashes Price Target

Stock Track11-07

Shares of Replimune Group Inc. (REPL) tumbled 5.06% in Friday's trading session following a significant price target cut by Leerink Partners. The biotech company, known for its work in oncolytic immunotherapies, saw its stock price target reduced from $13 to $11 by the investment firm, sparking concerns among investors about the company's near-term prospects.

The sharp decline comes amid a flurry of clinical research activity from Replimune. The company recently published two studies: one focusing on anti-PD-1-failed non-melanoma skin cancer (NMSC) and MSI-H/dMMR solid tumors, and another on RP1 immunotherapy for anti-PD-1-failed solid tumors. While these studies demonstrate Replimune's ongoing efforts in advancing cancer treatments, they appear to have done little to offset the negative sentiment generated by the lowered price target.

Investors and analysts will likely be closely watching Replimune's upcoming announcements and clinical trial results to gauge the company's potential for recovery. The biotech sector is known for its volatility, and Replimune's ability to deliver positive outcomes from its ongoing research could be crucial in reversing the current downward trend in its stock price.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1105330981?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-07 23:59","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1105330981","market":"hk","top_or_hot":-1,"title":"Stock Track | Replimune Group Plummets 5% as Leerink Partners Slashes Price Target","media":"Stock Track","content":"<p>Shares of Replimune Group Inc. (REPL) tumbled 5.06% in Friday's trading session following a significant price target cut by Leerink Partners. The biotech company, known for its work in oncolytic immunotherapies, saw its stock price target reduced from $13 to $11 by the investment firm, sparking concerns among investors about the company's near-term prospects.</p>\n\n<p>The sharp decline comes amid a flurry of clinical research activity from Replimune. The company recently published two studies: one focusing on anti-PD-1-failed non-melanoma skin cancer (NMSC) and MSI-H/dMMR solid tumors, and another on RP1 immunotherapy for anti-PD-1-failed solid tumors. While these studies demonstrate Replimune's ongoing efforts in advancing cancer treatments, they appear to have done little to offset the negative sentiment generated by the lowered price target.</p>\n\n<p>Investors and analysts will likely be closely watching Replimune's upcoming announcements and clinical trial results to gauge the company's potential for recovery. The biotech sector is known for its volatility, and Replimune's ability to deliver positive outcomes from its ongoing research could be crucial in reversing the current downward trend in its stock price.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Replimune Group Plummets 5% as Leerink Partners Slashes Price Target</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Replimune Group Plummets 5% as Leerink Partners Slashes Price Target\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-07 23:59</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Replimune Group Inc. (REPL) tumbled 5.06% in Friday's trading session following a significant price target cut by Leerink Partners. The biotech company, known for its work in oncolytic immunotherapies, saw its stock price target reduced from $13 to $11 by the investment firm, sparking concerns among investors about the company's near-term prospects.</p>\n\n<p>The sharp decline comes amid a flurry of clinical research activity from Replimune. The company recently published two studies: one focusing on anti-PD-1-failed non-melanoma skin cancer (NMSC) and MSI-H/dMMR solid tumors, and another on RP1 immunotherapy for anti-PD-1-failed solid tumors. While these studies demonstrate Replimune's ongoing efforts in advancing cancer treatments, they appear to have done little to offset the negative sentiment generated by the lowered price target.</p>\n\n<p>Investors and analysts will likely be closely watching Replimune's upcoming announcements and clinical trial results to gauge the company's potential for recovery. The biotech sector is known for its volatility, and Replimune's ability to deliver positive outcomes from its ongoing research could be crucial in reversing the current downward trend in its stock price.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"REPL","symbol_name":"Replimune Group Inc.","start_time":0,"source_url":"","article_id":"1105330981","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1105330981","pubTimestamp":1762531142,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Replimune Group Inc. (REPL) tumbled 5.06% in Friday's trading session following a significant price target cut by Leerink Partners. The biotech company, known for its work in oncolytic...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"REPL":"Replimune Group Inc."},"translate_title":"股票追踪|Leerink Partners大幅下调目标价，Replimune Group暴跌5%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"REPL":1},"content_text":"Shares of Replimune Group Inc. (REPL) tumbled 5.06% in Friday's trading session following a significant price target cut by Leerink Partners. The biotech company, known for its work in oncolytic immunotherapies, saw its stock price target reduced from $13 to $11 by the investment firm, sparking concerns among investors about the company's near-term prospects.\nThe sharp decline comes amid a flurry of clinical research activity from Replimune. The company recently published two studies: one focusing on anti-PD-1-failed non-melanoma skin cancer (NMSC) and MSI-H/dMMR solid tumors, and another on RP1 immunotherapy for anti-PD-1-failed solid tumors. While these studies demonstrate Replimune's ongoing efforts in advancing cancer treatments, they appear to have done little to offset the negative sentiment generated by the lowered price target.\nInvestors and analysts will likely be closely watching Replimune's upcoming announcements and clinical trial results to gauge the company's potential for recovery. The biotech sector is known for its volatility, and Replimune's ability to deliver positive outcomes from its ongoing research could be crucial in reversing the current downward trend in its stock price.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1105330981","isCrawlerRequest":true}